Efficacy of an 11-valent pneumococcal conjugate vaccine against radiologically confirmed pneumonia among children less than 2 years of age in the Philippines: A randomized, double-blind, placebo-controlled trial

Pediatric Infectious Disease Journal

Volumn 28, Issue 6, 2009, Pages 455-462

  Lucero, Marilla G ^a,e   Nohynek, Hanna ^b,f,g   Williams, Gail ^c   Tallo, Veronica ^a   Simões, Eric A F ^d   Lupisan, Socorro ^a   Sanvictores, Diozele ^a   Forsyth, Simon ^c   Puumalainen, Taneli ^b,f,g   Ugpo, Juanita ^a   Lechago, Marites ^a   De Campo, Margaret ^c   Abucejo Ladesma, Erma ^a   Sombrero, Lydia ^a   Nissinen, Antti ^b,f,g   Soininen, Anu ^b,f,g   Ruutu, Petri ^b,f,g   Riley, Ian ^c   Mäkelä, Helen P ^b,f,g  

^a RESEARCH INSTITUTE FOR TROPICAL MEDICINE   (Philippines)

^b Division of Health Protection   (Finland)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^e Department of Dermatology   (Philippines)

^f Department of Infectious Disease Surveillance and Control ^*  (Finland)

^g NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Childhood pneumonia; Pneumococcal conjugate vaccine; Randomized controlled trial

Indexed keywords

BCG VACCINE; DIPHTHERIA TOXOID; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; IMMUNOGLOBULIN G ANTIBODY; MEASLES VACCINE; ORAL POLIOMYELITIS VACCINE; PLACEBO; PNEUMOCOCCUS VACCINE; TETANUS TOXOID;

ANTIBODY RESPONSE; ARTICLE; BACTERIAL PNEUMONIA; CHILD; CHILD HEALTH CARE; CHILDHOOD DISEASE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIPHTHERIA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ENZYME IMMUNOASSAY; FEMALE; HEALTH PROGRAM; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INFANT; INJECTION SITE ERYTHEMA; INVASIVE PNEUMOCOCCAL DISEASE; MAJOR CLINICAL STUDY; MALE; PHILIPPINES; PNEUMOCOCCAL INFECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; TETANUS; THORAX RADIOGRAPHY; TREATMENT OUTCOME; VACCINATION;

EID: 67649556268     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31819637af     Document Type: Article

References (36)

1. Levine OS, O'Brien KL, Knoll M, et al. Pneumococcal vaccination in developing countries. Lancet. 2006;367:1880-1882.
2. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunoge-nicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J. 2000;19:187-195.
3. O'Brien K, Moulton L, Reid R, et al. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. Lancet. 2003;362:355-361.
4. Whitney CG, Pilishvili T, Farley MM, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet. 2006;368:1495-1502.
5. Klugman KP, Madhi SA, Huebner RE, et al. A trial of a 9-valent pneumo-coccal conjugate vaccine in children with and those without HIV infection. N Engl J Med. 2003;349:1341-1348.
6. Cutts FT, Zaman SM, Enwere G, et al. Efficacy of nine-valent pneumo-coccal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. (erratum: Lancet. 2005;366:328) Lancet. 2005;365:1139-1146.
7. Hansen J, Black S, Shinefield H, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs. Pediatr Infect Dis J. 2006;25:779-781.
8. Anonymous. Pneumococcal conjugate vaccine for childhood immunization. WHO position paper. Wkly Epidemiol Rec. 2007;82:93-104.
9. Lucero M, Dulalia V, Parreno R, et al. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and pneumonia with consolidation on x-ray in children under two years of age. Cochrane Database Syst Rev. 2004;4:CD004977.
10. Williams BG, Gouws E, Boschi-Pinto C, et al. Estimates of world-wide distribution of child deaths from acute respiratory infections. Lancet Infect Dis. 2002;2:25-32.
11. Philippine Health Statistics. Department of Health National Epidemiology Center. Manila, the Philippines; 2000.
12. Tupasi TE, Lucero MG, Magdangal DM, et al. Etiology of acute lower respiratory tract infection in children from Alabang, Metro Manila. Rev Infect Dis. 1990;12:929-939.
13. Lupisan S, Herva E, Sombrero LT, et al. Invasive bacterial infections of children in a rural province in central Philippines. Am J Trop Med Hyg. 2000;62:341-346.
14. Wuorimaa T, Dagan R, Eskola J, et al. Tolerability and immunogenicity of an eleven-valent pneumococcal conjugate vaccine in healthy toddlers. Pediatr Infect Dis J. 2001;20:272-277.
15. National Demographic and Health Survey. National Statistics Office, Manila, Philippines; 2003.
16. Puumalainen T, Quiambao B, Abucejo-Ladesma E, et al; for the ARIVAC Research Consortium. Clinical case review: a method to improve identification of true clinical and radiographic pneumonia in children meeting the World Health Organization definition for pneumonia. BMC Infect Dis. 2008;8:95.
17. World Health Organization Pneumonia Vaccine Trial Investigators' Group. Standardization of interpretation of chest radiographs for the diagnosis of pneumonia in children. Geneva, Switzerland: WHO; 2001. WHO/V&B/ 01.35.
18. World Health Organization Programme for the Control of Acute Respiratory Infections: acute respiratory infections in children: case management in small hospitals in developing countries. Geneva, Switzerland: WHO; 1990. WHO/ARI/90.5.
19. WHO Collaborating Centre for International Drug Monitoring. Adverse Reaction Terminology. Uppsala, December 2001. Available at: www. pharmadhoc.com/WHO-ART-Dictionary-Guide.pdf
20. Arcay JD, Ocampo AF, Solis RK, et al. Radiology quality assurance in a developing country setting: the 11-valent pneumococcal conjugate vaccinetrial, Bohol, Philippines. Vaccine. 2006;25:2528-2532.
21. Herva E, Sombrero L, Lupisan S, et al. Establishing a laboratory for surveillance of invasive bacterial infections in a tertiary care government hospital in a rural province in the Philippines. Am J Trop Med Hyg. 1999;60:1035-1040.
22. Sorensen UB. Typing of pneumococci by using 12 pooled antisera. J Clin Microbiol. 1993;31:2097-2100.
23. Käyhty H, Åhman H, Ronnberg PR, et al. Pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine is immunogenic in infants and children. J Infect Dis. 1995;172:1273-1278.
24. Ugpo J, Lucero MG, Williams G, et al. Reactogenicity and tolerability of a non-adjuvanted 11-valent diphtheria-tetanus toxoid pneumococcal conjugate vaccine in Filipino children. Vaccine. 2009;27:2723-2729.
25. Black S, Shinefield H, Ling S, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J. 2002;21:810-815.
26. Capeding MR, Sombrero LT, Lucero MG, et al. Serotype distribution and antimicrobial resistance of invasive Streptococcus pneumoniae isolates in Filipino children. J Infect Dis. 1994;169:479-480.
27. Obaro SK, Enwere GC, Deloria M, et al. Safety and immunogenicity of pneumococcal conjugate vaccine in combination with diphtheria, tetanus toxoid, pertussis and Haemophilus influenzae type b conjugate vaccine. Pediatr Infect Dis J. 2002;21:940-947.
28. Huebner RE, Mbelle N, Forrest B, et al. Immunogenicity after one, two or three doses and impact on the antibody response to coadministered antigens of a nonavalent pneumococcal conjugate vaccine in infants of Soweto, South Africa. Pediatr Infect Dis J. 2002;21:1004-1007.
29. Huebner RE, Mbelle N, Forrest B, et al. Long term antibody levels and booster responses in South African children immunized with nonavalent pneumococcal conjugate vaccine. Vaccine. 2004;22:2696-2700.
30. Madhi SA, Kuwanda L, Cutland C, et al. Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African Human Immunodeficiency Virus-infected and uninfected children. Pediatr Infect Dis J. 2005;24:410-416.
31. Dagan R, Goldblatt D, Maleckar JR, et al. Reduction of antibody response to an 11-valent pneumococcal vaccine coadministered with a vaccine containing acellular pertussis components. Infect Immun. 2004;72:5383-5391.
32. Berndt ER, Glennerster R, Kremer MR, et al. Advance market commitments for vaccines against neglected diseases: estimating costs and effectiveness. Health Econ. 2007;16:491-511.
33. Robinson K, Baughman W, Rothrock G, et al. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: opportunities for prevention in the conjugate vaccine era. JAMA. 2001;285: 1729-1735.
34. Ho PL, Chiu SS, Cheung CH, et al. Invasive pneumococcal disease burden in Hong Kong children. Pediatr Infect Dis J. 2006;25:454-455.
35. Eskola J, Takala AK, Kela E, et al. Epidemiology of invasive pneumococcal infections in children in Finland. JAMA. 1992;268:3323-3327.
36. Sombrero L, Sunico ME, Quiambao B, et al. Reliability of parental history of antibiotic use for Filipino children admitted with acute lower respiratory tract infection. Am J Trop Med Hyg. 1999;60:397-399.